Stifel Financial Corp Raises Stock Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Stifel Financial Corp lifted its stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) by 103.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 228,277 shares of the company's stock after acquiring an additional 116,175 shares during the quarter. Stifel Financial Corp's holdings in Elanco Animal Health were worth $2,764,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health during the third quarter worth approximately $35,000. Jones Financial Companies Lllp boosted its stake in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company's stock worth $51,000 after acquiring an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. grew its holdings in Elanco Animal Health by 221.2% in the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company's stock worth $60,000 after purchasing an additional 3,411 shares during the period. MRP Capital Investments LLC bought a new stake in Elanco Animal Health in the fourth quarter valued at $61,000. Finally, Blue Trust Inc. raised its holdings in shares of Elanco Animal Health by 47.7% during the fourth quarter. Blue Trust Inc. now owns 5,862 shares of the company's stock valued at $71,000 after purchasing an additional 1,894 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ELAN has been the subject of a number of research analyst reports. Piper Sandler decreased their target price on Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating for the company in a research report on Thursday, March 6th. Barclays lowered their target price on Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Morgan Stanley reduced their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating for the company in a research report on Wednesday, February 26th. Stifel Nicolaus dropped their price objective on shares of Elanco Animal Health from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Monday, April 14th. Finally, UBS Group decreased their target price on shares of Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $14.67.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction on Tuesday, March 11th. The stock was purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares of the company's stock, valued at $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.89% of the stock is currently owned by company insiders.

Elanco Animal Health Stock Performance

Elanco Animal Health stock traded up $2.54 during mid-day trading on Wednesday, reaching $12.05. 22,253,336 shares of the company's stock were exchanged, compared to its average volume of 5,023,212. The business's fifty day simple moving average is $9.83 and its 200 day simple moving average is $11.43. The company has a quick ratio of 1.31, a current ratio of 2.55 and a debt-to-equity ratio of 0.66. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $18.80. The firm has a market capitalization of $5.98 billion, a PE ratio of 30.13, a P/E/G ratio of 2.50 and a beta of 1.49.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Wednesday, May 7th. The company reported $0.37 EPS for the quarter, topping analysts' consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm's revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.34 EPS. On average, sell-side analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.